Answers are grounded in this paper and cite their sources.
A novel therapy for COPD involving the use of aerosolized hyaluronan (HA) was tested on a small cohort of COPD patients to determine both its safety and efficacy in reducing levels of desmosine and isodesmosine (DID), biomarkers for elastin degradation. In a 2-week, randomized, double-blind trial, 8 patients receiving 150 kDa HA (mean molecular weight) and 3 others given placebo did not show significant adverse effects with regard to spirometry, electrocardiograms, and hematological indices. Furthermore, measurements of DID in plasma from HA-treated patients indicated a progressive decrease over a 3-week period following initiation of treatment ( r =−0.98; p =0.02), whereas patients receiving placebo showed no reduction in DID ( r =−0.70; p =0.30). Measurements of sputum in the HA-treated group also revealed a progressive decrease in DID ( r =−0.97; p =0.03), but this finding was limited by the absence of similar measurements in the placebo group. Nevertheless, the results of this small, pilot study support a longer-term trial of HA in a larger population of COPD patients.
No takes yet. Share an insight, caveat, or question.
Cantor et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: